Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Karlin

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Cell Reports|November 15, 2018
Trisomy of a Down Syndrome Critical Region Globally Amplifies Transcription via HMGN1 OverexpressionCody T Mowery, Jaime M Reyes, Lucia Cabal-Hierro, et al.
Nature Genetics|January 31, 2018
Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastomaRhamy Zeid, Matthew A Lawlor, Evon Poon, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 27, 2024
Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY CohortT Chalopin, M Macro, O Decaux, et al.
Nature Genetics|March 30, 2016
Corrigendum: Mutations in the transcriptional repressor REST predispose to Wilms tumorShazia S Mahamdallie, Sandra Hanks, Kristen L Karlin, et al.
Nature Genetics|November 10, 2015
Mutations in the transcriptional repressor REST predispose to Wilms tumorShazia S Mahamdallie, Sandra Hanks, Kristen L Karlin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2016
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myelomaG Fouquet, B Pegourie, M Macro, et al.
British Journal of Haematology|May 15, 2024
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registryB Ferment, J Lambert, D Caillot, et al.
Leukemia|July 30, 2013
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patientsB Hebraud, X Leleu, V Lauwers-Cances, et al.
Cell Reports|December 3, 2014
The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressorKristen L Karlin, Gourish Mondal, Jessica K Hartman, et al.
Breast Cancer Research : BCR|September 13, 2014
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinaseXiaoyong Fu, Chad J Creighton, Nrusingh C Biswal, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Cell Reports|November 15, 2018
Trisomy of a Down Syndrome Critical Region Globally Amplifies Transcription via HMGN1 OverexpressionCody T Mowery, Jaime M Reyes, Lucia Cabal-Hierro, et al.
Nature Genetics|January 31, 2018
Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastomaRhamy Zeid, Matthew A Lawlor, Evon Poon, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 27, 2024
Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY CohortT Chalopin, M Macro, O Decaux, et al.
Nature Genetics|March 30, 2016
Corrigendum: Mutations in the transcriptional repressor REST predispose to Wilms tumorShazia S Mahamdallie, Sandra Hanks, Kristen L Karlin, et al.
Nature Genetics|November 10, 2015
Mutations in the transcriptional repressor REST predispose to Wilms tumorShazia S Mahamdallie, Sandra Hanks, Kristen L Karlin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2016
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myelomaG Fouquet, B Pegourie, M Macro, et al.
British Journal of Haematology|May 15, 2024
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registryB Ferment, J Lambert, D Caillot, et al.
Leukemia|July 30, 2013
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patientsB Hebraud, X Leleu, V Lauwers-Cances, et al.
Cell Reports|December 3, 2014
The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressorKristen L Karlin, Gourish Mondal, Jessica K Hartman, et al.
Breast Cancer Research : BCR|September 13, 2014
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinaseXiaoyong Fu, Chad J Creighton, Nrusingh C Biswal, et al.
Pageof 5